Zobrazeno 1 - 10
of 12
pro vyhledávání: '"H. Roschitzki-Voser"'
Autor:
Felip E; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Smit EF; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Molina-Vila MA; Laboratory of Oncology, Pangaea Oncology, Dexeus University Hospital, Barcelona, Spain., Dafni U; National and Kapodistrian University of Athens, Athens, Greece; Frontier Science Foundation Hellas, Athens, Greece., Massuti B; Medical Oncology Department, Hospital General Universitario Alicante, Alicante, Spain., Berghmans T; Institute Jules Bordet, Brussels, Belgium., de Marinis F; Thoracic Oncology Division, European Institute of Oncology IRCCS, Milan, Italy., Passiglia F; Department of Oncology, University of Turin, S. Luigi Hospital, Orbassano, Turin, Italy., Dingemans AC; Department of Pulmonology, Maastricht University Medical Center, Maastricht, the Netherlands & Department of Pulmonology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands., Cobo M; Unidad Gestion Intercentros of Medical Oncology. Regional and Virgen de la Victoria University Hospitals (IBIMA), Málaga, Spain., Viteri S; Instituto Oncológico Dr Rosell, Hospital Universitario Dexeus. Grupo QuironSalud, Barcelona, Spain., Britschgi C; Department of Medical Oncology and Hematology, University Hospital Zurich, Comprehensive Cancer Center Zurich, Zurich, Switzerland., Cuffe S; Department of Medical Oncology, St. James's Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland., Provencio M; Hospital Puerta de Hierro, Majadahonda Medical Oncology Service, Madrid, Spain., Merkelbach-Bruse S; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Cologne, Germany., Andriakopoulou C; Frontier Science Foundation Hellas, Athens, Greece., Kammler R; ETOP IBCSG Partners Foundation, Coordinating Center, Bern, Switzerland., Ruepp B; ETOP IBCSG Partners Foundation, Coordinating Center, Bern, Switzerland., Roschitzki-Voser H; ETOP IBCSG Partners Foundation, Coordinating Center, Bern, Switzerland., Peters S; Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland., Wolf J; Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany., Stahel R; ETOP IBCSG Partners Foundation, Coordinating Center, Bern, Switzerland. Electronic address: Rolf.Stahel@etop.ibcsg.org.
Publikováno v:
Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2022 Oct; Vol. 172, pp. 94-99. Date of Electronic Publication: 2022 Aug 12.
Autor:
Dafni U; National and Kapodistrian University of Athens, Athens, Greece; Frontier Science Foundation Hellas, Athens, Greece., Soo RA; National University Cancer Institute, Department of Haematology-Oncology, Singapore., Peters S; Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland., Tsourti Z; Frontier Science Foundation Hellas, Athens, Greece., Zygoura P; Frontier Science Foundation Hellas, Athens, Greece., Vervita K; Frontier Science Foundation Hellas, Athens, Greece., Han JY; National Cancer Center, Center for Lung Cancer, Goyang, Republic of Korea., De Castro J; Hospital Universitario La Paz, Medical Oncology Department, Madrid, Spain; Spanish Lung Cancer Group (SLCG), Barcelona, Spain., Coate L; Mid-Western Cancer Centre and University Hospital Limerick, Limerick, Ireland; Cancer Trials Ireland, Innovation House, Dublin, Ireland., Früh M; Cantonal Hospital St. Gallen, Oncology and Hematology, St. Gallen, Switzerland; Inselspital Bern, Department of Oncology, Bern, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland., Hashemi SMS; Amsterdam UMC, VU University Medical Center, Department of Pulmonary Diseases, Amsterdam, the Netherlands., Nadal E; Spanish Lung Cancer Group (SLCG), Barcelona, Spain; ICO L'Hospitalet, Medical Oncology Department, Barcelona, Spain., Carcereny E; Spanish Lung Cancer Group (SLCG), Barcelona, Spain; Institut Català d'Oncologia Badalona-Hospital Germans Trias i Pujol, B-ARGO Group, Medical Oncology Department, Badalona, Spain., Sala MA; Spanish Lung Cancer Group (SLCG), Barcelona, Spain; Hospital Universitario Basurto, Medical Oncology Department, Bilbao, Spain., Bernabé R; Spanish Lung Cancer Group (SLCG), Barcelona, Spain; Hospital Virgen del Rocio, Medical Oncology Department, Seville, Spain., Provencio M; Spanish Lung Cancer Group (SLCG), Barcelona, Spain; Hospital Puerta de Hierro, Majadahonda Medical Oncology Service, Madrid, Spain., Cuffe S; Cancer Trials Ireland, Innovation House, Dublin, Ireland; St. James's Hospital, Department of Medical Oncology, Dublin, Ireland., Roschitzki-Voser H; ETOP IBCSG Partners Foundation, Coordinating Office, Bern, Switzerland., Ruepp B; ETOP IBCSG Partners Foundation, Coordinating Office, Bern, Switzerland., Rosell R; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain; Catalan Institute of Oncology (ICO), Honorary Consultant, Barcelona, Spain., Stahel RA; ETOP IBCSG Partners Foundation, Coordinating Office, Bern, Switzerland. Electronic address: rolf.stahel@etop.ibcsg.org.
Publikováno v:
ESMO open [ESMO Open] 2022 Jun; Vol. 7 (3), pp. 100507. Date of Electronic Publication: 2022 Jun 10.
Autor:
Soo RA; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore., Han JY; National Cancer Center, Center for Lung Cancer, Goyang, Republic of Korea., Dafni U; National and Kapodistrian University of Athens, Athens, Greece; Frontier Science Foundation Hellas, Athens, Greece., Cho BC; Yonsei Cancer Center, Yonsei University College of Medicine, Division of Medical Oncology, Seoul, Republic of Korea., Yeo CM; Medical Oncology Department, Tan Tock Seng Hospital, Singapore, Singapore., Nadal E; Medical Oncology Department, ICO L'Hospitalet, Barcelona, Spain., Carcereny E; Medical Oncology Department, Institut Català d'Oncologia Badalona Hospital Germans Trias i Pujol, B-ARGO Group, Badalona, Spain., de Castro J; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain., Sala MA; Medical Oncology Department, Hospital Universitario Basurto, Bilbao, Spain., Bernabé R; Medical Oncology Department, Hospital Virgen del Rocio, Sevilla, Spain., Coate L; Mid-Western Cancer Centre and University Hospital Limerick, Limerick, Ireland., Provencio Pulla M; Hospital Puerta de Hierro, Majadahonda Medical Oncology Service, Madrid, Spain., Garcia Campelo R; Medical Oncology Department, Hospital Teresa Herrera, La Coruña, Spain., Cuffe S; Department of Medical Oncology, St. James's Hospital, Dublin, Ireland., Hashemi SMS; Department of Pulmonary Diseases, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands., Früh M; Cantonal Hospital St. Gallen, Oncology and Hematology, St. Gallen, Switzerland; Department of Oncology, Inselspital Bern, Bern, Switzerland., Massuti B; Medical Oncology Department, Hospital General Universitario Alicante, Alicante, Spain., Garcia-Sanchez J; Medical Oncology Service, Hospital Arnau Vilanova, Valencia, Spain., Dómine M; Department of Oncology, Hospital Universitario Fundacion Jimenez Díaz (IIS-FJD), Madrid, Spain., Majem M; Medical Oncology Department, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain., Sanchez-Torres JM; Medical Oncology Department, Hospital Universitario de la Princesa, Madrid, Spain., Britschgi C; Department of Medical Oncology and Hematology, University Hospital Zurich, Comprehensive Cancer Center Zurich, Zurich, Switzerland., Pless M; Cantonal Hospital Winterthur, Oncology and Haematology, Winterthur, Switzerland., Dimopoulou G; Frontier Science Foundation Hellas, Athens, Greece., Roschitzki-Voser H; European Thoracic Oncology Platform (ETOP), Coordinating Office, Bern, Switzerland., Ruepp B; European Thoracic Oncology Platform (ETOP), Coordinating Office, Bern, Switzerland., Rosell R; Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain; Catalan Institute of Oncology (ICO), Honorary Consultant, Barcelona, Spain., Stahel RA; European Thoracic Oncology Platform (ETOP), Coordinating Office, Bern, Switzerland. Electronic address: Rolf.Stahel@etop-eu.org., Peters S; Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland.
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2022 Feb; Vol. 33 (2), pp. 181-192. Date of Electronic Publication: 2021 Nov 26.
Autor:
Peters S; Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. Electronic address: Solange.Peters@chuv.ch., Danson S; Department of Oncology and Metabolism & Sheffield Experimental Cancer Medicine Centre, University of Sheffield, Weston Park Hospital, Sheffield, United Kingdom., Ejedepang D; Headquarters, European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium., Dafni U; National and Kapodistrian University of Athens & Frontier Science Foundation-Hellas, Athens, Greece., Hasan B; Headquarters, European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium., Radcliffe HS; Amgen Inc, Uxbridge, United Kingdom., Bustin F; Centre Hospitalier Regional De La Citadelle, Liège, Belgium., Crequit J; Centre Hospitalier De Beauvais, France., Coate L; Mid-Western Cancer Centre, University Hospital Limerick, Limerick, Ireland; Cancer Trials, Ireland., Guillot M; Hospital Universitari Son Espases, Palma, Spain; Spanish Lung Cancer Group (GECP), Spain., Surmont V; Universitair Ziekenhuis Gent, Belgium., Rauch D; Spital STS AG Thun, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Switzerland., Rudzki J; Innsbruck Universitaetsklinik, Austria; Central European Cooperative Oncology Group (CECOG), Austria., O'Mahony D; Cork University Hospital, Ireland; Cancer Trials, Ireland., Barneto Aranda I; Hospital Universitario Reina Sofia, Córdoba, Spain; Spanish Lung Cancer Group (GECP), Spain., Scherz A; Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Switzerland., Tsourti Z; Frontier Science Foundation-Hellas, Athens, Greece., Roschitzki-Voser H; Coordinating Office, European Thoracic Oncology Platform (ETOP), Bern, Switzerland., Pochesci A; Headquarters, European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium., Demonty G; Amgen NV Diegem, Belgium., Stahel RA; Coordinating Office, European Thoracic Oncology Platform (ETOP), Bern, Switzerland., O'Brien M; Department of Medical Oncology, Royal Marsden Hospital Sutton, UK.
Publikováno v:
Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2021 Nov; Vol. 161, pp. 76-85. Date of Electronic Publication: 2021 Sep 09.
Autor:
Peters S; Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. Electronic address: Solange.Peters@chuv.ch., Danson S; Department of Oncology and Metabolism & Sheffield Experimental Cancer Medicine Centre, University of Sheffield, Weston Park Hospital, Sheffield, United Kingdom., Hasan B; European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium., Dafni U; School of Health Sciences, National and Kapodistrian University of Athens & Frontier Science Foundation-Hellas, Athens, Greece., Reinmuth N; Asklepios Kliniken GmbH, Asklepios Fachkliniken Muenchen, Gauting, Germany., Majem M; Department of Medical Oncology, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain., Tournoy KG; Faculty of Medicine and Life Sciences, Ghent University and Onze-Lieve-Vrouwziekenhuis (OLV), Aalst, Belgium., Mark MT; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Department of Medical Oncology, Cantonal Hospital Graubuenden, Chur, Switzerland., Pless M; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Department of Medical Oncology and Hematology, Cantonal Hospital Winterthur, Winterthur, Switzerland., Cobo M; Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain; Unidad Gestion Intercentros of Medical Oncology. Regional and Virgen de la Victoria University Hospitals (IBIMA), Málaga, Spain., Rodriguez-Abreu D; Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain; Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain., Falchero L; Department of Pneumology and Thoracic Oncology, Hopital Nord-Ouest, Villefranche-sur-Saône Cedex, France., Moran T; Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain; Department of Medical Oncology, Institut Català d'Oncologia (ICO) Badalona, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona Applied Research Group in Oncology (B-ARGO), Barcelona, Spain., Ortega Granados AL; Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain; Department of Medical Oncology, Hospital Universitario de Jaén, Jaén, Spain., Monnet I; Department of Pneumology, Centre Hopitalier Intercommunal De Créteil, Créteil, France., Mohorcic K; Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia., Sureda BM; Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain; El Instituto de Investigación Sanitaria y Biomédica de Alicante (SABIAL), Hospital Universitario Alicante, Alicante, Spain., Betticher D; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Department of Medical Oncology, Fribourg Cantonal Hospital (HFR), Fribourg, Switzerland., Demedts I; Department of Pulmonary Diseases, AZ Delta, Roeselare, Belgium., Macias JA; Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain; Department of Hematology and Oncology, Hospital General Universitario Morales Meseguer, Murcia, Spain., Cuffe S; Cancer Trials Ireland, Dublin, Ireland; Department of Medical Oncology, St. James's Hospital, Dublin, Ireland., Luciani A; Department of Medical Oncology, Ospedale San Paolo, Milano, Italy., Sanchez JG; Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain; Department of Medical Oncology, University Hospital Arnau de Vilanova, Valencia, Spain., Curioni-Fontecedro A; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Department for Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland., Gautschi O; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Cantonal Hospital Lucerne, Lucern, Switzerland., Price G; Department of Medical Oncology, Aberdeen Royal Infirmary NHS Grampian, Aberdeen, United Kingdom., Coate L; Cancer Trials Ireland, Dublin, Ireland; Mid-Western Cancer Centre, University Hospital Limerick, Limerick, Ireland., von Moos R; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Department of Medical Oncology, Cantonal Hospital Graubuenden, Chur, Switzerland., Zielinski C; Clinical Division of Oncology, Medical University Vienna, Vienna, Austria; Central European Cooperative Oncology Group, Vienna, Austria., Provencio M; Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain; Department of Medical Oncology, Hospital Puerta de Hierro-Majadahonda, Madrid, Spain., Menis J; European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology Department, Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padova, Italy., Ruepp B; European Thoracic Oncology Platform (ETOP), Bern, Switzerland., Pochesci A; European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium., Roschitzki-Voser H; European Thoracic Oncology Platform (ETOP), Bern, Switzerland., Besse B; European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium; Gustave Roussy Cancer Center Villejuif, Paris Saclay University, Orsay, France., Rabaglio M; European Thoracic Oncology Platform (ETOP), Bern, Switzerland., O'Brien MER; Department of Medical Oncology, Royal Marsden Hospital, Sutton, United Kingdom., Stahel RA; Department for Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2020 Oct; Vol. 15 (10), pp. 1647-1656. Date of Electronic Publication: 2020 Jun 18.
Autor:
Peters S; Centre Hospitalier Universitaire Vaudois (CHUV), Département d'Oncologie, Lausanne, Switzerland., Felip E; Vall d'Hebron University Hospital, Institute of Oncology (VHIO), Barcelona, Spain., Dafni U; Frontier Science Foundation-Hellas & National and Kapodistrian University of Athens, Greece., Belka C; Department of Radiation Oncology and DZL Munich, University Hospital, LMU Munich, Germany., Guckenberger M; University Hospital Zurich, Department for Radiation Oncology, University of Zurich, Switzerland., Irigoyen A; Hospital Virgen De La Salud, Department of Medical Oncology, Toledo, Spain., Nadal E; Catalan Institute of Oncology, Department of Medical Oncology, IDIBELL L'Hospitalet, Barcelona, Spain., Becker A; Amsterdam University Medical Center, Department of Respiratory Diseases, Amsterdam, the Netherlands., Vees H; Clinic Hirslanden, Radiation Oncology, Zürich, Switzerland., Pless M; Cantonal Hospital Winterthur, Medical Oncology, Winterthur, Switzerland., Martinez-Marti A; Vall d'Hebron University Hospital, Institute of Oncology (VHIO), Barcelona, Spain., Tufman A; Ludwig Maximilian University of Munich (LMU), Medizinische Klinik and Poliklinik V, German Center for Lung Research, Munich, Germany., Lambrecht M; University Hospitals Gasthuisberg, Department of Radiotherapy-Oncology, Leuven, Belgium., Andratschke N; University Hospital Zurich, Department for Radiation Oncology, University of Zurich, Switzerland., Piguet AC; European Thoracic Oncology Platform (ETOP), Bern, Switzerland., Kassapian M; Frontier Science Foundation-Hellas, Athens, Greece., Roschitzki-Voser H; European Thoracic Oncology Platform (ETOP), Bern, Switzerland., Rabaglio-Poretti M; European Thoracic Oncology Platform (ETOP), Bern, Switzerland., Stahel RA; University Hospital Zurich, Department of Haematology and Oncology, Switzerland., Vansteenkiste J; University Hospitals Gasthuisberg, Department of Respiratory Diseases, Leuven, Belgium., De Ruysscher D; Maastro Clinic, Department of Radiation Oncology Maastricht, the Netherlands. Electronic address: dirk.deruysscher@maastro.nl.
Publikováno v:
Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2019 Jul; Vol. 133, pp. 83-87. Date of Electronic Publication: 2019 May 03.
Autor:
Dziadziuszko R; Medical University of Gdansk, Department of Oncology and Radiotherapy, Gdansk, Poland., Smit EF; VU University Medical Center, Department of Pulmonary Diseases & Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., Dafni U; Frontier Science Foundation-Hellas & National and Kapodistrian University of Athens, Athens, Greece., Wolf J; University Hospital Cologne, Department of Internal Medicine, Cologne, Germany., Wasąg B; Medical University of Gdansk, Department of Biology and Genetics, Gdansk, Poland., Biernat W; Medical University of Gdansk, Department of Pathology, Gdansk, Poland., Finn SP; Cancer Molecular Diagnostics, St. James's Hospital and Trinity College, Dublin, Ireland., Kammler R; European Thoracic Oncology Platform (ETOP), Bern, Switzerland., Tsourti Z; Frontier Science Foundation-Hellas, Athens, Greece., Rabaglio M; European Thoracic Oncology Platform (ETOP), Bern, Switzerland., Ruepp B; European Thoracic Oncology Platform (ETOP), Bern, Switzerland., Roschitzki-Voser H; European Thoracic Oncology Platform (ETOP), Bern, Switzerland., Stahel RA; University Hospital Zurich, Clinic of Oncology, Zurich, Switzerland., Felip E; Vall d'Hebron University Hospital, Institute of Oncology, Barcelona, Spain., Peters S; Centre Hospitalier Universitaire Vaudois (CHUV), Département d'Oncologie, Lausanne, Switzerland. Electronic address: Solange.Peters@chuv.ch.
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2019 Jun; Vol. 14 (6), pp. 1086-1094. Date of Electronic Publication: 2019 Feb 27.
Autor:
R.A. Soo, J.-Y. Han, U. Dafni, B.C. Cho, C.M. Yeo, E. Nadal, E. Carcereny, J. de Castro, M.A. Sala, R. Bernabé, L. Coate, M. Provencio Pulla, R. Garcia Campelo, S. Cuffe, S.M.S. Hashemi, M. Früh, B. Massuti, J. Garcia-Sanchez, M. Dómine, M. Majem, J.-M. Sanchez-Torres, C. Britschgi, M. Pless, G. Dimopoulou, H. Roschitzki-Voser, B. Ruepp, R. Rosell, R.A. Stahel, S. Peters, Rolf Stahel, Solange Peters, Ross Soo, Ji-Youn Han, Martin Früh, Mariano Provencio, Linda Coate, Urania Dafni, Anita Hiltbrunner, Barbara Ruepp, Heidi Roschitzki-Voser, Adriana Gasca-Ruchti, Nino Giacomelli, Rosita Kammler, Nesa Marti, Lionel Nobs, Mariana Pardo-Contreras, Rita Pfister, Anne-Christine Piguet, Sabrina Ribeli-Hofmann, Virginia Rodriguez Martinez, Susanne Roux, Magdalena Sanchez-Hohl, Mirjam Schneider, Robin Schweri, Sandra Troesch, Isabel Zigomo, Zoi Tsourti, Panagiota Zygoura, Marie Kassapian, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Maria Fernandez, Eva Pereira, Carolina Simona, Lisa Tucker, Jillian Burnes, Aisling Barrett, Meghan McGrillen, Catherine Berset, Christine Biaggi, Martin Reist, Priska Rentsch, Sinead Cuffe, Sayed Hashemi, Ernest Nadal, Enric Carcereny, Javier de Castro, Maria Angeles Sala, Bernabé Reyes, Mariano Provencio Pulla, Rosario Garcia Campelo, Bartomeu Massutí, Jose Garcia, Manuel Dómine, Margarita Majem, Jose Miguel Sanchez, Christian Britschgi, Miklos Pless, Chong Ming Yeo, Byoung Chul Cho
Publikováno v:
ANNALS OF ONCOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Annals of oncology : official journal of the European Society for Medical Oncology, 33(2), 181-192. Oxford University Press
ETOP 10-16 BOOSTER Collaborators 2022, ' A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations : the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial ', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 33, no. 2, pp. 181-192 . https://doi.org/10.1016/j.annonc.2021.11.010
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Annals of oncology : official journal of the European Society for Medical Oncology, 33(2), 181-192. Oxford University Press
ETOP 10-16 BOOSTER Collaborators 2022, ' A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations : the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial ', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 33, no. 2, pp. 181-192 . https://doi.org/10.1016/j.annonc.2021.11.010
Background: While osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the standard treatment in patients with advanced non-small-cell lung cancer (NSCLC) with sensitising EGFR and acquired T790M
Autor:
Linda Coate, Zoi Tsourti, Gaston Demonty, Frederique Bustin, Daniel Rauch, H. Roschitzki-Voser, A. Pochesci, Veerle Surmont, M Guillot, Jakob Rudzki, Dunson Ejedepang, Isidoro Barneto Aranda, Baktiar Hasan, Rolf A. Stahel, Urania Dafni, Mary O'Brien, Hoi-Shen Radcliffe, Amina Scherz, Jacky Crequit, Deirdre O'Mahony, Sarah Danson, Solange Peters
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 161
Introduction\ud \ud The efficacy of adding denosumab to standard first-line chemotherapy for advanced NSCLC patients has been evaluated in two separate randomised trials (SPLENDOUR and AMGEN-249). In this pooled analysis, we will assess the combinati
Autor:
Johan Vansteenkiste, Amanda Tufman, M. Guckenberger, Dirk De Ruysscher, Miklos Pless, N. Andratschke, Maarten Lambrecht, Alex Martinez-Marti, Antonio Irigoyen, M. Kassapian, A.-C. Piguet, H. Roschitzki-Voser, Enriqueta Felip, Manuela Rabaglio-Poretti, Rolf A. Stahel, Urania Dafni, Claus Belka, H. Vees, Solange Peters, E. Nadal, A. Becker
Publikováno v:
Peters, S, Felip, E, Dafni, U, Belka, C, Guckenberger, M, Irigoyen, A, Nadal, E, Becker, A, Vees, H, Pless, M, Martinez-Marti, A, Tufman, A, Lambrecht, M, Andratschke, N, Piguet, A C, Kassapian, M, Roschitzki-Voser, H, Rabaglio-Poretti, M, Stahel, R A, Vansteenkiste, J & De Ruysscher, D 2019, ' Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial ', Lung Cancer, vol. 133, pp. 83-87 . https://doi.org/10.1016/j.lungcan.2019.05.001
Lung Cancer, 133, 83-87. Elsevier Ireland Ltd
Lung Cancer, 133, 83-87. Elsevier Ireland Ltd
Objectives: Chemo-radiotherapy (CRT) and concurrent PD-1 inhibition has shown promising results in preclinical models. So far, the feasibility of delivering concurrent CRT and PD-1/PD-L1 inhibition has never been assessed in a clinical trial.Material